Single product, business line or region

Hong Kong IPO disclosure precedents · 257 companies, 267 items

most revenue from one product, project, site, business line or region (e.g. a single mine, a single drug, one flagship product, projects and customers concentrated in one province)

2026-09-30PHIP
Amicro Technology Co., Ltd.珠海一微科技股份有限公司

The revenue from intelligent mobile robotic solutions constituted 94.2%, 94.9%, 95.0%, 84.8% and 99.0% of our total revenue in 2023, 2024, 2025 and the four months ended April 30, 2025 and 2026, respectively

Summary · p. 11

The revenue contribution of multi-modal robotic solutions was relatively high since its launch while that of single modal robotic solutions decreased in 2024 compared to 2023, subsequently remained relatively stable in 2025, mainly as we allocated more R&D and marketing resources to the development and promotion of multi-modal robotic solutions during these periods.

Summary · p. 3

In addition, the profitability of our multi-modal robotic solutions improved significantly, with gross profit margin increasing from 15.3% in 2024 to 44.0% in 2025.

Business · p. 199
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-09-27Application Proof
Voyager Intelligent Systems Limited上海寅家电子科技股份有限公司

We generated a substantial portion of our revenue from sales of intelligent driving solutions and intelligent cockpit solutions, accounting for 100.0%, 100.0%, 98.4%, 100.0% and 97.6% of our total revenue in 2023, 2024 and 2025 and the six months ended June 30, 2025 and 2026, respectively.

Financial Information · p. 210

As a result, changes in our solutions and products mix and revenue mix may also affect our overall gross profit margin and subsequently other aspects of our business performance.

Financial Information · p. 210
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-09-25PHIP
Shenzhen Transsion Holdings Co., Ltd.深圳传音控股股份有限公司

During the Track Record Period, revenue from sales of smartphones contributed a majority of our total revenue, and fluctuations in the sales of smartphones affected our overall revenue.

Financial Information · p. 209

Our future success depends on our ability to (i) maintain the sales growth of our existing products that meet the evolving demand and taste of consumers, and (ii) introduce new products and services to our existing consumer base and attract new consumers to expand our market share.

Financial Information · p. 209
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-09-22Prospectus
Shenzhen Camsense Technologies Co., Ltd.深圳市欢创科技股份有限公司06802.HK

During the Track Record Period, we successfully expanded beyond our legacy triangulation LiDAR products, which accounted for 98.3% and 94.1% of our total revenue in 2023 and 2024, respectively, into dTOF LiDAR and line laser sensor products that we commercially launched in 2024 following years of in-house research and development.

Summary · p. 17

As a result, the revenue contribution from triangulation LiDAR products declined to 65.7% and 47.1% of our total revenue in 2025 and the three months ended March 31, 2026, materially reducing our reliance on a single product line and broadening our addressable market across robotic vacuums and other applications.

Summary · p. 17
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-09-22Application Proof
Guangdong Rising Mineral-Rich Mountain Copper Co., Ltd.广东省广晟大宝山铜业股份有限公司

Our sole mining asset is the Dabaoshan Mine, a large-scale open-pit polymetallic mine located in Shaxi Town, Qujiang District, Shaoguan City, Guangdong Province, the PRC.

Summary · p. 1

During the Track Record Period, a substantial portion of our revenue was derived from the sale of copper concentrates, sulphur concentrates and magnetic sulphur concentrates.

Financial Information · p. 183

Our current designed mining capacity is 3.30 Mt/a. We plan to expand our total mining and processing capacity to 6.60 Mt/a.

Financial Information · p. 183
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-09-21Prospectus
Shenzhen Kinwong Electronic Co., Ltd.深圳市景旺电子股份有限公司03228.HK

For example, revenue generated from the sales of automotive electronics PCB accounted for 40.7%, 45.9% and 45.4% of our total revenue in 2023, 2024 and 2025, respectively.

Financial Information · p. 203

The prevailing trend of electrification and intelligentization in the automotive industry has influenced, and will continue to impact our order intake, production capacity utilization, and working capital requirements.

Financial Information · p. 203

According to CIC, we are the world’s largest automotive electronics PCB manufacturer with a market share of 10.6%, and rank eleventh among all PCB providers worldwide with a market share of 2.5% by revenue in 2025.

Financial Information · p. 203
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-09-21Application Proof
Dynamic Electronics Co., Ltd.超颖电子电路股份有限公司

Revenue from automotive electronics remained our largest application category during the Track Record Period, although its contribution to total revenue decreased from 68.8% in 2023 to 51.4% in the six months ended June 30, 2026, reflecting increased revenue contributions from data storage as well as communications and AI servers.

Financial Information · p. 159
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-09-13PHIP
Hunan Junxin Environmental Protection Co., Ltd.湖南军信环保股份有限公司

As of the Latest Practicable Date, for most of our projects that are in operation, and the majority of our customers, were situated in Hunan, with others located overseas.

Summary · p. 7

This geographic, and customer, concentration exposes us to region-specific risks, including population decline, changes in local government policies, economic conditions, and environmental regulations.

Summary · p. 7

In April 2026, we received a notice of award for the Changsha Hexi Waste-to-Energy Incineration Power Plant Project (with a planned treatment capacity of 4,000 tons per day).

Summary · p. 13
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-09-03Application Proof
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.深圳信立泰药业股份有限公司

In terms of sales revenue, our major marketed drugs comprise XinLiTan, TaiJia, FuLiTan, and EnNaLuo, which in aggregate contributed 62.0% of our total sales revenue of pharmaceuticals in the six months ended June 30, 2026.

Business · p. 153

Subsequent to the NRDL re-negotiation, we lowered the retail price of XinLiTan in 2026.

Business · p. 154

The retail price and sales revenue of TaiJia were primarily affected by China’s centralized procurement programs.

Business · p. 154
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-31Prospectus
Excelland Robotics (Wuxi) Co. Ltd.优地机器人(无锡)股份有限公司03231.HK

In FY2023, FY2024, FY2025 and 3M2026 revenue generated from sales of Yoshop vending robots, mainly H2 and H8 models, to Customer C amounted to approximately RMB58.5 million, RMB34.6 million, RMB54.8 million and RMB18.5 million, respectively, representing approximately 99.5%, 99.4%, 99.6% and 99.8% of our revenue from sales of Yoshop vending robots, and approximately 24.0%, 12.9%, 17.3% and 24.1% of our total revenue in each year/period during the Track Record Period, respectively.

Business · p. 122

Accordingly, Customer C contributed to the commercialisation and market application of the Yoshop vending robots, but not to their research and development.

Business · p. 122

Our Directors are of the view that our customer concentration with Customer C during the Track Record Period was mainly due to the complementary strengths of Customer C and us, combining our technical expertise, ability to customise AI training models to detect different objects and to provide complete solutions on synergy between vending machine with Customer C's mature vending machine operation systems and vast customer base.

Business · p. 149
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-31Application Proof
Ningbo Sunny Smart Autotech Company Limited宁波舜宇智行科技股份有限公司

Our results of operations and financial condition are primarily driven by the development of the vehicle optical product market, especially the vehicle camera products we focus on, which represent a key product category and are the main source of our revenue.

Financial Information · p. 221

During the Track Record Period, our revenue generated from sales of vehicle camera products amounted to RMB4,984.0 million, RMB5,679.5 million, RMB6,863.1 million, RMB3,209.0 million and RMB3,441.2 million in 2023, 2024, 2025 and the six months ended June 30, 2025 and 2026, respectively.

Financial Information · p. 222
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-31Application Proof
Guangxi Yuchai Marine and Genset Power Co., Ltd.广西玉柴船电动力股份有限公司

For FY2023, FY2024, FY2025, 1H2025 and 1H2026, our revenue from the sales of large engines amounted to RMB853.3 million, RMB1,374.1 million, RMB2,321.6 million, RMB1,027.3 million and RMB1,807.3 million, respectively, accounting for 26.4%, 34.5%, 37.7%, 34.5% and 40.2% of our total revenue for the same respective periods, and gross profit margins for large engines were 25.5%, 30.2%, 33.9%, 29.8% and 38.8% for the same respective periods.

Financial Information · p. 226

During the Track Record Period, we experienced a significant growth in our operating results, which has been driven to a large extent by increasing demands for our power generator engine and power generation set products in the data center industry in China, among others.

Financial Information · p. 225
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-28Application Proof
SHENZHEN CAPCHEM TECHNOLOGY CO., LTD.深圳新宙邦科技股份有限公司

In 2023, 2024, 2025 and for the six months ended June 30, 2025 and 2026, revenue derived from battery chemicals amounted to RMB5,053.1 million, RMB5,115.6 million, RMB6,679.4 million, RMB2,815.4 million, and RMB5,748.2 million, representing 67.6%, 65.3%, 69.4%, 66.4% and 77.1% of our total revenue for the respective periods.

Financial Information · p. 208

As the profit margins, cost structures and market dynamics vary across our business segments, changes in the relative contribution of these products have had, and are expected to continue to have, a direct impact on our overall gross profit margin, and in turn, expected to affect our results of operations and financial condition more broadly.

Financial Information · p. 208
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-28Application Proof
HANGZHOU TANGJI MEDICAL TECHNOLOGY CO., LTD.杭州糖吉医疗科技股份有限公司

As we commenced commercial sales of our Core Product in 2024, our financial performance is directly linked to our ability to drive continual market penetration and revenue growth.

Financial Information · p. 237

To extend our reach to broader, currently underserved patient populations, we are actively exploring opportunities to expand approved indications and target patient populations, as well as introducing new specifications of our Core Product.

Financial Information · p. 237
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-27Application Proof
DIZAL PHARMACEUTICAL CO., LTD.迪哲(江苏)医药股份有限公司

ZEGFROVY^®^ and golidocitinib were commercially launched in August 2023 and June 2024 in Chinese Mainland, respectively.

Financial Information · p. 240

We did not have any commercialized products prior to the Track Record Period.

Summary · p. 14

Our net losses during the Track Record Period were primarily due to (i) the limited number of approved drugs and the limited commercialization time for ZEGFROVY^®^ and golidocitinib, (ii) economies of scale still materializing, particularly as we build our internal commercialization team in its early stages, (iii) significant R&D investments aligned with the advancement of our product pipeline, (iv) the affordable pricing strategy for ZEGFROVY^®^ and golidocitinib upon NRDL inclusion to capture greater market share, (v) significant selling and distribution expenses incurred to promote ZEGFROVY^®^ and golidocitinib and to build market awareness among healthcare professionals, and (vi) investments in attracting and retaining talent.

Summary · p. 14
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-26Application Proof
Zenshine Pharmaceuticals (Nanjing) Group Co., Ltd.征祥医药(南京)集团股份有限公司

Sebaloxavir marboxil tablets, our Core Product, was the first and only commercialized product in our pipeline.

Financial Information · p. 222

In 2025 and the six months ended June 30, 2026, we recorded revenue of RMB5.3 million and RMB2.5 million, respectively.

Financial Information · p. 222

The ability of our drug candidates to demonstrate favorable safety and efficacy profiles in clinical trials, and to obtain timely regulatory approvals, is critical to our ability to diversify revenue streams and achieve sustainable growth.

Financial Information · p. 222
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-25Application Proof
Ugreen Group Limited深圳市绿联科技股份有限公司

In 2023, 2024 and 2025 and the six months ended June 30, 2025 and 2026, charging products and accessories, office products and audio and visual products together accounted for 93.2%, 93.7%, 87.1%, 89.2% and 86.8% of our total revenue for the respective year/period.

Financial Information · p. 206

Specifically, our revenue generated from storage products increased by 213.2% from RMB391.4 million in 2024 to RMB1,225.8 million in 2025, which further increased by 85.5% from RMB414.8 million for the six months ended June 30, 2025 to RMB769.6 million during the same period in 2026.

Financial Information · p. 206
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-24Application Proof
Shanghai Eigencomm Technologies Co., Ltd.上海移芯通信科技股份有限公司

Because our revenue during the Track Record Period was primarily concentrated in NB-IoT and Cat.1bis products, our profitability profile was more directly exposed to the prevailing industry-wide ASP compression than more diversified peers whose product portfolios included a larger proportion of higher-speed products.

Business · p. 185

We expect these products to contribute to our revenue in 2026, The revenue and gross profit contribution from these products are expected to partially offset the ASP and margin pressure from our existing chip products in 2026.

Summary · p. 14
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-21Application Proof
Eaglerise Electric & Electronic (CHINA) Co., Ltd.伊戈尔电气股份有限公司

During the Track Record Period, revenues generated from our medium-voltage transformer equipment products for the years ended December 31, 2023, 2024, 2025 and the six months ended June 30, 2026 were approximately RMB2,492.0 million, RMB3,256.0 million, RMB3,546.1 million and RMB1,869.3 million, respectively, representing 68.9%, 70.7%, 68.0% and 70.2% of our Group’s total revenues for the same period.

Summary · p. 2

During the Track Record Period, our medium-voltage transformer equipment products accounted for 68.9%, 70.7%, 68.0% and 70.2% of our total revenue in 2023, 2024, 2025 and the six months ended June 30, 2026, respectively.

Summary · p. 1

We believe that continued diversification of our product portfolio will not only strengthen our market position, but also create new revenue and profit streams and further support our long-term growth.

Financial Information · p. 217
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-21Application Proof
Zhuhai Kingsware Artificial Intelligence Co., Ltd.珠海金智维人工智能股份有限公司

Financial services | 185,847 | 85.8 | 190,099 | 78.1 | 177,929 | 69.5 | 35,322 | 76.8 | 50,021 | 76.8

Summary · p. 10

Our gross profit margin decreased slightly to 51.6% in 2025 primarily due to higher project delivery costs incurred as we continued to expand our business into non-financial sectors.

Summary · p. 10
The company's explanation, the adviser's view and the page in the filing: see Matters
1 / 14

Tell us